RxDoctor Payments DataLook up a doctor →

Nigam Patel, MD

Family Medicine · Des Plaines, ILNPI 1477656684

Payments from drug & device makers

$33,764in general payments, 2019–2025

Across 1,378 payments — averaging $24.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$12K
  • AbbVie$3K
  • AstraZeneca$2K
  • Corcept Therapeutics$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • plus $11K from 52 others

What the payments were for

  • Speaking & faculty fees$10,05030%
  • Travel & lodging$8453%
  • Food & beverage$22,76867%
  • Education$1010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer60$12,190
AbbVie(2 entities)210$2,722
AstraZeneca130$2,352
Corcept Therapeutics113$2,227
Novo Nordisk116$1,750
Lilly USA, LLC80$1,239
Boehringer Ingelheim73$1,198
GSK66$972
Bayer34$820
Amgen(2 entities)42$769
Sanofi-aventis U.S. LLC36$660
USWM, LLC46$653
Xeris Pharmaceuticals, Inc.34$597
Indivior Inc.27$570
Braeburn Inc.43$487
Merck32$450
Mannkind Corporation21$385
Gilead19$369
Sunovion Pharmaceuticals Inc.24$360
Novartis13$271
Orexo US, Inc.15$268
Esperion Therapeutics, Inc.14$209
Ironwood Pharmaceuticals, Inc13$208
Johnson & Johnson13$199
Sanofi Pasteur Inc.9$197
Dexcom, Inc.5$170
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)8$153
Cranial Technologies, Inc9$139
Mylan Specialty L.p.7$109
Abbott7$98
Lexicon Pharmaceuticals, Inc.5$94
Recordati_rare_diseases_inc.4$80
E.r. Squibb & Sons, L.L.C.5$75
Hikma Pharmaceuticals USA4$71
Pear Therapeutics (US), Inc.4$60
Teva Pharmaceuticals USA, Inc.3$54
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$54
Otsuka America Pharmaceutical, Inc.3$52
Biohaven Pharmaceuticals, Inc.3$47
Exact Sciences2$39
Sumitomo Pharma America, Inc.2$37
Mayne Pharma Commercial LLC3$31
MDD US Operations, LLC2$27
Redhill Biopharma Inc.2$25
Daiichi Sankyo Inc.1$23
Ultragenyx Pharmaceutical Inc.1$22
Axsome Therapeutics, Inc.1$20
Eisai Inc.1$19
Radius Health, Inc.1$19
Lundbeck LLC1$17
Phathom Pharmaceuticals, Inc.1$16
Cipher Pharmaceuticals US LLC1$16
Biohaven Pharmaceutical Holding Company Ltd.1$14
Takeda Pharmaceuticals U.S.A., Inc.1$14
Coopersurgical, Inc.1$14
Shield Therapeutics Inc1$12
Athena Bioscience, LLC1$12
Genentech USA, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,764 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$191
Medicare patients
38
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KorlymMifepristone48$1,011,678
JardianceEmpagliflozin82$125,109
TrulicityDulaglutide44$82,198
RybelsusSemaglutide29$58,902
Synjardy XrEmpagliflozin/Metformin Hcl38$56,840
OzempicSemaglutide34$44,287
MounjaroTirzepatide23$29,654
FarxigaDapagliflozin Propanediol32$27,843
DescovyEmtricitabine/Tenofov Alafenam11$23,270
SublocadeBuprenorphine11$22,591
KerendiaFinerenone16$21,814
CreonLipase/Protease/Amylase11$17,919
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl125$12,941
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$11,817
Novolog FlexpenInsulin Aspart18$7,378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Corcept TherapeuticsKorlym$2,227$1,011,67848 claims
Boehringer IngelheimJardiance, Synjardy Xr$1,198$181,950120 claims
Lilly USA, LLCTrulicity, Mounjaro$1,239$111,85267 claims
Novo NordiskRybelsus, Ozempic$1,750$103,18963 claims
AstraZenecaFarxiga$2,352$27,84332 claims
GileadDescovy$369$23,27011 claims
Indivior Inc.Sublocade$570$22,59111 claims
BayerKerendia$820$21,81416 claims
AbbVieCreon$2,722$17,91911 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl$71$13,675152 claims
GSKArexvy, Shingrix$972$8,64734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Des Plaines

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →